menu
    • menu
    [{"orgOrder":0,"company":"Chime Biologics","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Humanigen"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hunan Mabgeek Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chime Biologics \/ Hunan Mabgeek Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Hunan Mabgeek Biotechnology"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hunan Mabgeek Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chime Biologics \/ Chime Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Chime Biologics"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Leads Biolabs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Chime Biologics \/ Leads Biolabs"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pucotenlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chime Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Domain Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"DT-7012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chime Biologics \/ Domain Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chime Biologics \/ Domain Therapeutics"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hope Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chime Biologics \/ Hope Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chime Biologics \/ Hope Medicine"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"SRB5","moa":"CCR9","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chime Biologics \/ Chime Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Chime Biologics \/ Chime Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Chime Biologics

    Menu

    Chime Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRB5

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Recipient : SunRock Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SunRock Biopharma, Chime Biologics Collaborate on Anti-CCR9 Antibody SRB5 Development

                            Details : The collaboration aims to advance SRB5, an unconjugated antibody targeting CCR9, for the treatment of inflammatory bowel disease (IBD).

                            Product Name : SRB5

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 20, 2025

                            Lead Product(s) : SRB5

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Recipient : SunRock Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MG-K10

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Hunan Mabgeek Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10

                            Details : The collaboration aims to advancing the MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic dermatitis and asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            February 21, 2025

                            Lead Product(s) : MG-K10

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Hunan Mabgeek Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MG-K10

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Hunan Mabgeek Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chime, Mabgeek Hit MG-K10 PPQ Milestone for Atopic Dermatitis Drug

                            Details : MG-K10, a humanized anti-IL-4Rα monoclonal antibody, is being investigated for treating Th2-mediated inflammatory diseases such as moderate-to-severe atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 03, 2025

                            Lead Product(s) : MG-K10

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Hunan Mabgeek Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-7012

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Domain Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Domain Therapeutics and Chime Announce Manufacturing Deal for Anti-Ccr8 Cancer Antibody

                            Details : Through the agreement, the company will focus on the clinical development of DT-7012, a CCR8 antibody candidate. Currently, it is being evaluated in preclinical trial studies for Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : DT-7012

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Domain Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Hope Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antib...

                            Details : Under the terms of agreement, Chime Biologics will provide one-stop-shop CMC solution for Hope Medicine's HMI-115 monoclonal antibody from technology transfer, process optimization, process characterization, process validation, BLA filing support, to com...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Hope Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LBL-007,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leads Biolabs

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Developm...

                            Details : The agreement aims to accelerate LBL-007, a novel antibody targeting the LAG-3 pathway, development and manufacturing for speedy clinical advancement for solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 30, 2023

                            Lead Product(s) : LBL-007,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leads Biolabs

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pucotenlimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial P...

                            Details : Puyouheng (pucotenlimab injection), anti-PD-1 monoclonal antibody has been conditionally approved for marketing by NMPA, is approved for patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient advanced solid ...

                            Product Name : Puyouheng

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : Pucotenlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Chime Biologics

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

                            Details : Chime Biologics will produce lenzilumab bulk drug substance and drug product for Humanigen for commercial sale following receipt of the requisite regulatory authorizations or approvals in regions outside of the U.S including Europe, the United Kingdom, I...

                            Product Name : Humaneered

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth